JPMorgan raised the firm’s price target on Rapt Therapeutics (RAPT) to $57 from $55 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- Rapt Therapeutics price target lowered to $56 from $58 at Barclays
- RAPT Therapeutics Advances with Strong Financial Backing
- Rapt Therapeutics shares ‘exceptionally compelling,’ says Clear Street
- Promising Clinical and Financial Developments Drive Buy Rating for RAPT Therapeutics
- Buy Rating for RAPT Therapeutics Driven by Promising Ozureprubart Data and Strategic Growth Plans